Equillium Inc. and Biocon Limited reported positive topline results from a Phase 2 study of itolizumab for treating moderate to severe ulcerative colitis, showing 23.3% clinical remission at 12 weeks compared to 20.0% for adalimumab and 10.0% for placebo.